SG10201408059QA - 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases - Google Patents

5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases

Info

Publication number
SG10201408059QA
SG10201408059QA SG10201408059QA SG10201408059QA SG10201408059QA SG 10201408059Q A SG10201408059Q A SG 10201408059QA SG 10201408059Q A SG10201408059Q A SG 10201408059QA SG 10201408059Q A SG10201408059Q A SG 10201408059QA SG 10201408059Q A SG10201408059Q A SG 10201408059QA
Authority
SG
Singapore
Prior art keywords
dihydropyrido
oxo
kinase inhibitors
cardiovascular diseases
pyrimidine derivatives
Prior art date
Application number
SG10201408059QA
Inventor
Philippe Beauverger
Guillaume Begis
Sandrine Biscarrat
Olivier Duclos
Gary Mccort
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG10201408059QA publication Critical patent/SG10201408059QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
SG10201408059QA 2010-01-08 2011-01-06 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases SG10201408059QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1050103A FR2955109B1 (en) 2010-01-08 2010-01-08 5-OXO-5,8-DIHYDRO-PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE

Publications (1)

Publication Number Publication Date
SG10201408059QA true SG10201408059QA (en) 2015-02-27

Family

ID=42244354

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201408059QA SG10201408059QA (en) 2010-01-08 2011-01-06 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases
SG2012050241A SG182417A1 (en) 2010-01-08 2011-01-06 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012050241A SG182417A1 (en) 2010-01-08 2011-01-06 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases

Country Status (17)

Country Link
US (1) US8975250B2 (en)
EP (1) EP2521726B1 (en)
JP (1) JP2013516447A (en)
KR (1) KR20120112768A (en)
CN (1) CN102791710A (en)
AR (1) AR079850A1 (en)
AU (1) AU2011206475A1 (en)
BR (1) BR112012016816A2 (en)
CA (1) CA2786537A1 (en)
FR (1) FR2955109B1 (en)
HK (1) HK1177207A1 (en)
MX (1) MX2012007951A (en)
RU (1) RU2012133968A (en)
SG (2) SG10201408059QA (en)
TW (1) TWI464170B (en)
UY (1) UY33167A (en)
WO (1) WO2011086306A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2954943B1 (en) * 2010-01-07 2013-03-01 Sanofi Aventis ARYLSULFONAMIDE PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
US8901305B2 (en) * 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
AU2014206834B2 (en) * 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
DE102014201651A1 (en) * 2014-01-30 2015-07-30 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Isoxazole derivatives for use in the treatment and / or prophylaxis of heart disease
US20210017174A1 (en) 2018-03-07 2021-01-21 Bayer Aktiengesellschaft Identification and use of erk5 inhibitor
TW202035375A (en) 2018-09-25 2020-10-01 美商卡都瑞恩醫藥有限責任公司 Aminopyrimidine compound
WO2020253608A1 (en) * 2019-06-18 2020-12-24 Peking University Antagonists of camkii-delta 9 and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
CA2563669A1 (en) 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
FR2873118B1 (en) * 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
JPWO2006049215A1 (en) 2004-11-02 2008-05-29 大日本住友製薬株式会社 Concomitant medications for treating autoimmune diseases
WO2007033232A1 (en) * 2005-09-14 2007-03-22 Janssen Pharmaceutica, N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2917412B1 (en) * 2007-06-13 2009-08-21 Sanofi Aventis Sa 7-ALKYNYL, 1,8-NAPHTHYRIDONES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2917413B1 (en) * 2007-06-13 2009-08-21 Sanofi Aventis Sa 7-ALKYNYL-1,8-NAPHTHYRIDONES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
MX2010002115A (en) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders.
WO2009042906A1 (en) 2007-09-26 2009-04-02 Regents Of The University Of Colorado Compositions and methods for camkii inhibitors and uses thereof
AU2008318656A1 (en) * 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Biomarker for assessing response to FMS treatment
FR2933700B1 (en) * 2008-07-08 2010-07-30 Sanofi Aventis PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2933701A1 (en) * 2008-07-08 2010-01-15 Sanofi Aventis ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2954943B1 (en) * 2010-01-07 2013-03-01 Sanofi Aventis ARYLSULFONAMIDE PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF

Also Published As

Publication number Publication date
WO2011086306A9 (en) 2011-10-27
RU2012133968A (en) 2014-02-20
HK1177207A1 (en) 2013-08-16
WO2011086306A1 (en) 2011-07-21
CA2786537A1 (en) 2011-07-21
CN102791710A (en) 2012-11-21
JP2013516447A (en) 2013-05-13
TW201139434A (en) 2011-11-16
FR2955109B1 (en) 2012-09-07
AR079850A1 (en) 2012-02-22
EP2521726B1 (en) 2013-12-18
MX2012007951A (en) 2012-11-21
US20120277220A1 (en) 2012-11-01
SG182417A1 (en) 2012-08-30
UY33167A (en) 2011-08-31
AU2011206475A1 (en) 2012-08-02
BR112012016816A2 (en) 2019-09-24
EP2521726A1 (en) 2012-11-14
KR20120112768A (en) 2012-10-11
US8975250B2 (en) 2015-03-10
TWI464170B (en) 2014-12-11
FR2955109A1 (en) 2011-07-15

Similar Documents

Publication Publication Date Title
HRP20171724T1 (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
ZA201307839B (en) Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors
PL2419428T3 (en) Imidazo[1,2-a]pyridine derivatives as fgfr kinase inhibitors for use in therapy
EP2608669A4 (en) NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
AP2013007159A0 (en) Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase
AP2014007899A0 (en) 2-Amino, 6-phenyl substituted pyrido [2,3-D] pyrimidine derivatives useful as RAF kinase inhibitors
HK1189229A1 (en) Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
ZA201200982B (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
ZA201105896B (en) [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors
IL227526A0 (en) 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives their use as pde9a inhibitors
EP2525659A4 (en) PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
IL224903A (en) Imidazo[4,5-c] quinolines as dna-pk inhibitors
IL217798A0 (en) Pyrrolo [1,2-b]pyridazine derivatives as janus kinase inhibitors
EP2563125A4 (en) Azaindoles as janus kinase inhibitors
HK1200447A1 (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors 1h-[2,3-b]
SG10201408059QA (en) 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases
SG11201408816QA (en) 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
EP2523552A4 (en) Pyrazolo[1,5-a]pyrimidines as mark inhibitors
EP2490693A4 (en) PYRAZOLO [3,4-b]PYRIDIN-4-ONE KINASE INHIBITORS
BRPI0906985A2 (en) Pyrido [4,3-d] pyrimidinone derivatives as kinase inhibitors